For patients with early-stage HER2-positive breast cancer, 4 cycles of doxorubicin and cyclophosphamide in neoadjuvant treatment can significantly shrink the tumor size and increase the pCR rate (20). The gene discussed is ERBB2; the disease is breast carcinoma.